Testosterone and Longevity in Men

Testosterone sits at the intersection of real medicine and aggressive marketing, which makes it hard to discuss clearly. Men’s testosterone tends to decline gradually with age, and that fact has been packaged into a sweeping promise: restore it and reclaim vitality, muscle, and years of life. The evidence supports a much narrower and more careful story than the promise suggests.

Three things that get conflated

A lot of confusion comes from blending three separate questions into one.

Age-related decline — average testosterone drifts down with age. This is common and, on its own, not necessarily a disease.
Symptomatic hypogonadism — some men have genuinely low testosterone with symptoms, a recognized clinical condition that can warrant treatment.
Longevity — whether raising testosterone in aging men extends lifespan is a distinct question, and the weakest-supported of the three.

Treating a man with documented deficiency and bothersome symptoms is well-established medicine. Prescribing testosterone to healthy aging men to live longer is not.

What the evidence does and doesn’t show

Gel capsules, capsules, medicine — illustrating Testosterone and Longevity in Men

Observational studies have linked low endogenous testosterone to higher mortality. A systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism (2011), pooling roughly 16,000 men, found low testosterone associated with increased all-cause and cardiovascular death — but with substantial between-study heterogeneity, and the authors cautioned that confounding and reverse causation (illness lowering testosterone, rather than the reverse) cannot be excluded.

The most direct safety data come from the TRAVERSE trial (New England Journal of Medicine, 2023), which randomized 5,246 men aged 45–80 with hypogonadism (testosterone below 300 ng/dL) and pre-existing or high cardiovascular risk to transdermal testosterone gel or placebo. Over a mean follow-up of about 33 months, testosterone was noninferior to placebo for major adverse cardiac events (7.0% vs 7.3%). Importantly, the trial tested cardiovascular safety in symptomatic men — not lifespan extension in healthy ones. Mask, protection, virus — illustrating Testosterone and Longevity in Men

The risk side of the ledger

TRAVERSE was not entirely reassuring. The testosterone group had higher rates of atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%), along with more fractures. Therapy also suppresses natural production and fertility and requires monitoring of blood counts and the prostate. These trade-offs are why self-prescription is unwise.

The takeaway

The honest framing keeps the three questions apart. Age-related decline is normal; symptomatic deficiency may merit treatment under medical care; longevity benefit is not demonstrated. Even the most rigorous trial to date set out to show that treating low-T men was reasonably safe — not that testosterone is an anti-aging drug. Be skeptical of it marketed as one.